StreetInsider.com News Articles

10X Genomics (TXG) PT Raised to $30 at Deutsche Bank

Wed, 03 Jun 2026 07:14:25 -0400

Deutsche Bank analyst Justin Bowers raised the price target on 10X Genomics (NASDAQ: TXG) to $30.00 (from $23.00) while maintaining a Hold rating.

Form 4 10x Genomics, Inc. For: May 22 Filed by: Hindson Benjamin J.

Wed, 27 May 2026 17:57:00 -0400

si-local-file:///var/storage/secattach/20260527/26559333.html

Form 4 10x Genomics, Inc. For: May 22 Filed by: Hindson Benjamin J.

Wed, 27 May 2026 17:57:00 -0400

si-local-file:///var/storage/secattach/20260527/26559333.html

Form 4 10x Genomics, Inc. For: May 22 Filed by: Saxonov Serge

Wed, 27 May 2026 17:57:00 -0400

si-local-file:///var/storage/secattach/20260527/26559335.html

Form 4 10x Genomics, Inc. For: May 22 Filed by: Saxonov Serge

Wed, 27 May 2026 17:57:00 -0400

si-local-file:///var/storage/secattach/20260527/26559335.html

Form 4 10x Genomics, Inc. For: May 22 Filed by: Taich Adam

Wed, 27 May 2026 17:56:00 -0400

si-local-file:///var/storage/secattach/20260527/26559332.html

Form 4 10x Genomics, Inc. For: May 22 Filed by: Taich Adam

Wed, 27 May 2026 17:56:00 -0400

si-local-file:///var/storage/secattach/20260527/26559332.html

Form 144 10x Genomics, Inc. Filed by: Saxonov Serge

Tue, 26 May 2026 16:56:00 -0400

si-local-file:///var/storage/secattach/20260526/26551001.html

Form 144 10x Genomics, Inc. Filed by: Saxonov Serge

Tue, 26 May 2026 16:56:00 -0400

si-local-file:///var/storage/secattach/20260526/26551001.html

Form 144 10x Genomics, Inc. Filed by: Saxonov Serge

Fri, 22 May 2026 20:32:00 -0400

si-local-file:///var/storage/secattach/20260522/26543389.html

Form 144 10x Genomics, Inc. Filed by: Saxonov Serge

Fri, 22 May 2026 20:32:00 -0400

si-local-file:///var/storage/secattach/20260522/26543389.html

Form 144 10x Genomics, Inc. Filed by: Hindson Benjamin J.

Fri, 22 May 2026 18:27:00 -0400

si-local-file:///var/storage/secattach/20260522/26543180.html

Form 144 10x Genomics, Inc. Filed by: Hindson Benjamin J.

Fri, 22 May 2026 18:27:00 -0400

si-local-file:///var/storage/secattach/20260522/26543180.html

Form 144 10x Genomics, Inc. Filed by: Taich Adam

Fri, 22 May 2026 17:40:00 -0400

si-local-file:///var/storage/secattach/20260522/26543018.html

Form 144 10x Genomics, Inc. Filed by: Taich Adam

Fri, 22 May 2026 17:40:00 -0400

si-local-file:///var/storage/secattach/20260522/26543018.html

10X Genomics (TXG) PT Raised to $22 at Morgan Stanley

Tue, 12 May 2026 08:34:36 -0400

Morgan Stanley analyst Kallum Titchmarsh raised the price target on 10X Genomics (NASDAQ: TXG) to $22.00 (from $20.00) while maintaining a Equalweight rating.

10X Genomics (TXG) PT Raised to $20 at JPMorgan

Tue, 12 May 2026 07:59:51 -0400

JPMorgan analyst Casey Woodring raised the price target on 10X Genomics (NASDAQ: TXG) to $20.00 (from $17.00) while maintaining a Neutral rating.

Form 10-Q 10x Genomics, Inc. For: Mar 31

Fri, 08 May 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260508/26456662.html

Form 10-Q 10x Genomics, Inc. For: Mar 31

Fri, 08 May 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260508/26456662.html

10x Genomics (TXG) Misses Q1 EPS by 4c

Thu, 07 May 2026 16:29:21 -0400

10x Genomics (NASDAQ: TXG) reported Q1 EPS of ($0.10), $0.04 worse than the analyst estimate of ($0.06). Revenue for the quarter came in at $150.8 million versus the consensus estimate of $146.52 million.

GUIDANCE:

10x Genomics sees FY2026 revenue of $600-625 million, versus the consensus of $612.74 million.

For earnings history and earnings-related data on 10x Genomics (TXG) click here.

10x Genomics (TXG) Misses Q1 EPS by 4c

Thu, 07 May 2026 16:29:21 -0400

GUIDANCE:

10x Genomics sees FY2026 revenue of $600-625 million, versus the consensus of $612.74 million.

For earnings history and earnings-related data on 10x Genomics (TXG) click here.

10x Genomics Reports First Quarter 2026 Financial Results

Thu, 07 May 2026 16:05:00 -0400

PLEASANTON, Calif., May 7, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2026.